A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
The aim of this study was to seek a better treatment for patients with inoperable or recurrent stomach cancer. Seventy patients were randomly allocated to receive courses of treatment with either A (5-Fluorouracil plus radiotherapy) or B (5-Fluorouracil plus Imidazole Carboxamide Dimethyl Triazeno plus Vincristine plus Bis-Chloroethyl Nitrosourea plus radiotherapy). Only 59 of these patients were evaluable. The median survival time of patients allocated to Group A was 220 days and Group B was 199 days. Seventeen of 31 patients in Group A and 10 of 28 patients in Group B had objectively documented remission. The median survival time of responders was 222 days for Group A and 410 for Group B. While it would appear that those patients who respond to the more intensive treatment do better, a larger percentage of patients responded to the simpler treatment regimen of 5-Fluorouracil plus radiotherapy.